# Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease

> **NCT04157933** · PHASE1 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** 009-A1
- **DRUG:** 009-A2
- **DRUG:** 009-A3
- **DRUG:** 009-A0
- **DRUG:** 009-B1 (active --> placebo) crossover
- **DRUG:** 009-B2 (placebo --> active) crossover

## Key facts

- **NCT ID:** NCT04157933
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-03-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04157933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04157933, "Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04157933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*